Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 408Observational 21Expanded_access 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Stromal Tumors 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Imatinib Mesylate × Clear all
NCT01613053 2015-04-24

MACS2226

Novartis

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00854841 2009-03-03

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Pusan National University Hospital

Available
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡